The discovery of the pathogenetic role of BCR-ABL and the advent of tyrosine kinase inhibitors has revolutionized the prognosis for Philadelphia-positive chronic myeloid leukemia (CML). Nevertheless, many challenges remain. In eight concise chapters, this book provides an expert overview of the state-of-the-art in addressing CML. Coverage includes diagnosis, risk classification, disease genetics, molecular monitoring, treatment options, prognostic factors and future prospects for disease management and the possibility of cure.
